2. Neurological Disease

Neurological Disease

Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162315
    MAGL-IN-16
    MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC50 value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress.
    MAGL-IN-16
  • HY-162330
    HDAC6-IN-36
    HDAC6-IN-36 (compound 11d) is an inhibitor of HDAC6 with IC50 value of 8.64 nM. HDAC6-IN-36 induces neurite outgrowth of PC12 cells without producing toxic effects.
    HDAC6-IN-36
  • HY-162336
    Casein kinase 1δ-IN-15 2765264-27-3
    Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC50 of 0.045 μM.
    Casein kinase 1δ-IN-15
  • HY-162338
    BChE-IN-29
    BChE-IN-29 (Compound 27a) is a BChE inhibitor (IC50: 0.078 μM and 0.74 μM for BChE and AChE respectively). BChE-IN-29 has anti-inflammatory activity and can be used for research of AD.
    BChE-IN-29
  • HY-162339
    BChE-IN-30
    BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC50: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD.
    BChE-IN-30
  • HY-162347
    Nav1.7-IN-13 2776235-57-3
    Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity.
    Nav1.7-IN-13
  • HY-162359
    BIO-7488 2573211-25-1 99.44%
    BIO-7488 is a potent, selective, oral active and CNS-penetrant IRAK4 inhibitor with the IC50 of 0.6 nM and > 30 μM for IRAK4 and hERG, respectively.
    BIO-7488
  • HY-162363
    MD6a
    MD6a is a melatonin derivative with inhibitroy activity towards PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR/HSF-1 signaling. MD6a a neuroprotective effect.
    MD6a
  • HY-162364
    p38-α MAPK-IN-7
    p38-α MAPK-IN-7 (compound 4) is a p38α-MAPK inhibitor with an IC50 value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production.
    p38-α MAPK-IN-7
  • HY-162388
    TIM-098a
    TIM-098a is a selective AAK1 inhibitor with an IC50 of 0.24 µM. TIM-098a has no inhibitory activity against CaMKK isoforms. TIM-098a inhibits AAK1-regulated endocytosis by suppressing AAK1 kinase activity.
    TIM-098a
  • HY-162454
    DA-023 2585643-97-4
    DA-023 (Compound 4) is a selective positive allosteric modulator (PAM) of EAAT2 with an EC50 value of 1 nM.
    DA-023
  • HY-162491
    JR-6
    JR-6 is a Gi/o pathway biased and muscarinic M2 selective partial agonist.
    JR-6
  • HY-162523
    hMAO-B-IN-8
    hMAO-B-IN-8 (Compound 23) is a hMAO-B, eeAChE, COX-2 and 5-LOX inhibitor, with IC50 values of 0.037 μM, 0.071 μM, 14.3 μM and 0.59 μM, respectively. hMAO-B-IN-8 can be used for the research of Alzheimer's disease.
    hMAO-B-IN-8
  • HY-162539
    T2-BDP589
    T2-BDP589 is a RIPK1 fluorescent probe, and can be used for the NanoBRET assay.
    T2-BDP589
  • HY-162552
    KOR/DOR agonist 1
    KOR/DOR agonist 2 is a KOR and DOR opioid receptors agonist with Ki values of 0.14 nM, and 0.93 nM, respectively. KOR/DOR agonist 2 shows significant antinociceptive effects. KOR/DOR agonist 2 penetrates the blood-brain barrier.
    KOR/DOR agonist 1
  • HY-162573
    Monoamine Oxidase B inhibitor 5 2969160-15-2
    Monoamine Oxidase B inhibitor 5 (Compound 16d) is a selective and reversible inhibitor for monoamine oxidase B (hMAO-B) with an IC50 of 67.3 nM and a Ki of 82.5 nM. Monoamine Oxidase B inhibitor 5 exhibits good pharmacokinetic characters and weak toxicity in rats model. Monoamine Oxidase B inhibitor 5 alleviates MPTP-induced (HY-15608) motor impairment in Parkinson’s mouse model. Monoamine Oxidase B inhibitor 5 is blood-brain barrier (BBB) penetrate.
    Monoamine Oxidase B inhibitor 5
  • HY-162585
    5-HT1AR agonist 1
    5-HT1AR agonist 1 (Compound A3) emerges as a relatively balanced multi-target activity profile, including 5-HT1AR agonist with an EC50 value of 34 nM, SERT reuptake ihibitor (IC50 =12 nM), NET reuptake inhibitor (IC50 =78 nM) and DAT reuptake inhibitor (IC50 =135 nM). 5-HT1AR agonist 1 performs significant antidepressant effects and exhibits excellent bioavailability and low clearance in mice, which is promising for research in the field of antidepressant drugs.
    5-HT1AR agonist 1
  • HY-162591
    MR33317
    MR33317 is an inhibitor of acetylcholinesterase with an IC50 value of 41nM. MR33317 is also an agonist at brain 5-HT4 receptors.
    MR33317
  • HY-162596
    NRL-1049 1973494-16-4
    NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC50: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice.
    NRL-1049
  • HY-162606
    MAO-A/B-IN-3 315210-31-2
    MAO-A/B-IN-3 (Compound 12) stands out as a key dual MAO-AChE inhibitor, displaying excellent multi-target efficacy against MAO-A, MAO-B, and AChE with IC50 values of 67 nM, 29 nM, and 1370 nM respectively. MAO-A/B-IN-3 is adept at altering the A site (hydrophobic ring) and C site (semicarbazone chain) within ketone amine-based MTDLs to bolster the inhibitory potential against MAO-A/B while notably diminishing activity against AChE. MAO-A/B-IN-3 is poised for research applications in the field of neurodegenerative diseases.
    MAO-A/B-IN-3
Cat. No. Product Name / Synonyms Application Reactivity
  •  
  •